Takeda Pharmaceutical Company Limited

Takeda Pharmaceuticals – Product Catalog (A–Z)

Adcetris → Generic: brentuximab vedotin → Indication: Hodgkin lymphoma, systemic ALCL, CD30+ lymphomas → Dose: IV infusion 50 mg vials

Amitiza → Generic: lubiprostone → Indication: Chronic idiopathic constipation (CIC), IBS-C, opioid-induced constipation → Dose: Capsules 8 mcg, 24 mcg

Alofisel → Generic: darvadstrocel (allogeneic stem cell therapy) → Indication: Complex perianal fistulas in Crohn’s disease → Dose: Intralesional injection

Dexilant / Dexilant SoluTab → Generic: dexlansoprazole → Indication: GERD, erosive esophagitis → Dose: Capsules 30–60 mg; ODT 30 mg

Entyvio → Generic: vedolizumab → Indication: Ulcerative colitis, Crohn’s disease (integrin α4β7 inhibitor) → Dose: IV infusion 300 mg; SC 108 mg

Fascalta (pipeline, Japan) → Generic: TAK-573 (anti-CD38–attenuated IFNα fusion) → Indication: Multiple myeloma → Dose: IV infusion (trial)

Gammagard Liquid → Generic: immune globulin IV (human) → Indication: Primary immunodeficiency, CIDP → Dose: IV infusion 10% solution

Gattex / Revestive → Generic: teduglutide → Indication: Short bowel syndrome → Dose: SC injection 5 mg daily

Hydrea / Siklos → Generic: hydroxyurea (adult / pediatric formulations) → Indication: Sickle cell disease, certain leukemias → Dose: Capsules 500 mg; scored tabs 100–1000 mg

Iclusig → Generic: ponatinib → Indication: CML, Ph+ ALL (T315I mutation–resistant cases) → Dose: Tablets 15–45 mg

Lonsurf → Generic: trifluridine + tipiracil → Indication: Metastatic colorectal cancer, gastric cancer → Dose: Tabs 15/6.14 mg, 20/8.19 mg

Nesina → Generic: alogliptin → Indication: Type 2 diabetes mellitus (DPP-4 inhibitor) → Dose: Tablets 6.25–25 mg

Ninlaro → Generic: ixazomib citrate → Indication: Multiple myeloma (oral proteasome inhibitor) → Dose: Capsules 2.3–4 mg

Oncaspar (legacy Shire) → Generic: pegaspargase → Indication: Acute lymphoblastic leukemia (ALL) → Dose: IV/IM injection vials 750 IU/m²

Replagal → Generic: agalsidase alfa → Indication: Fabry disease (enzyme replacement) → Dose: IV infusion 0.2 mg/kg q2w

Rozlytrek (regional collaborations) → Generic: entrectinib → Indication: NTRK+ solid tumors, ROS1+ NSCLC → Dose: Capsules 100–200 mg

Signifor / Signifor LAR → Generic: pasireotide → Indication: Cushing’s disease, acromegaly → Dose: SC injection 0.3–0.9 mg bid; LAR IM 10–60 mg monthly

Tak-003 (Qdenga) → Generic: live attenuated tetravalent dengue vaccine → Indication: Dengue prevention → Dose: SC injection, 2-dose series

Takhzyro → Generic: lanadelumab → Indication: Prophylaxis of hereditary angioedema (HAE) → Dose: Prefilled syringe/pen 300 mg SC q2–4w

Tretten → Generic: coagulation factor XIII A-subunit (recombinant) → Indication: Congenital FXIII deficiency → Dose: IV infusion 250–1250 IU

Trintellix (ex-U.S.: Brintellix) → Generic: vortioxetine → Indication: Major depressive disorder (MDD) → Dose: Tablets 5–20 mg

Uloric → Generic: febuxostat → Indication: Gout (hyperuricemia) → Dose: Tablets 40–80 mg

Vonvendi → Generic: von Willebrand factor (recombinant) → Indication: von Willebrand disease → Dose: IV infusion vials 650–1300 IU

Vyvanse (Elvanse) → Generic: lisdexamfetamine dimesylate (from Shire) → Indication: ADHD, binge eating disorder → Dose: Capsules 20–70 mg; chewables